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Introduction
Myelofibrosis (MF) is a clonal disease, arising 
as a result of somatic mutations in pluripotent stem 
cells. This leads to proliferation of atypical megakaryo-
cytes and disfunction of the bone marrow microenvi-
ronment. Deregulation of JAK-STAT (Janus kinase 
— signal transducers and activators of transcription) 
pathway plays a key role in MF pathogenesis. Most 
patients carry mutation of the tyrosine kinase gene 
JAK2 V617F in exon 14. In patients with wild-type 
JAK2 gene, about 10% have mutation in the MPL 
W515L/K gene coding receptor for thrombopoietin, 
and in 80% of the remaining patients a mutation in the 
calreticulin gene (CALR) can be detected. All three 
described mutations lead to constitutive activation of 
JAK-STAT pathway, which results in increased secre-
tion of proinflammatory cytokines, including interleukin 
8, 10, 15, and tumour necrosis factor alpha (TNFa), as 
well as increased secretion of growth factors: vascular 
endothelial growth factor (VEGF), basic fibroblast 
growth factor (bFGF), platelet-derived growth factor 
(PDGF), and transforming growth factor beta (TGFß). 
Excess of enumerated particles increases fibrosis, 
induces extra-medullary haematopoiesis, stimulates 
angiogenesis, and raises constitutional catabolism. Lack 
of either of these three mutations, found in about 10% 
of patients, is correlated with poor prognosis. Besides 
the presence of the described “driver” mutations, seve-
ral types of mutations in genes regulating epigenetic 
changes can be found (including ASXL1, EZH2, TET2, 
DNMT3A, IDH1/2, SRFS2, SRF3B1, TP53). Detection 
of at least one mutation in ASXL1, EZH2, SRSF2, and 
IDH1/2 genes determines high molecular risk (HMR), 
associated with shorter overall survival (OS) and higher 
risk of blastic transformation.
Described clinical and molecular features were 
incorporated in the newest prognostic scales, which 
supports optimal clinical management of patients 
with MF. In 2009, the International Working Group 
— Myeloproliferative Neoplasms Research and Treat-
ment (IWG-MRT) collaboration developed the Interna-
tional Prognostic Scoring System (IPSS) scale, based on 
five independent progression risk factors assessed at the 
time of MF diagnosis. This included: age over 65 years; 
presence of systematic symptoms; haemoglobin (Hb) 
concentration lower than 10 g/dl; hyperleukocytosis over 
25 G/l; and the presence of at least 1% of blasts in pe-
ripheral blood smear. The IPSS scale was subsequently 
expanded into Dynamic IPSS (DIPSS), which included 
the possibility of acquisition of the aforementioned risk 
factors during the course of the disease, and provides 
prognostic stratification at any point of MF duration. 
In the DIPSS Plus scale, three additional independ-
ent prognostic factors were included: dependency on 
blood transfusions; unfavourable karyotype (trisomy 8; 
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monosomy 7/7q–; i(17q); inv(3); monosomy 5/5q– or 
12p–; rearrangement of 11q23); and thrombocytopaenia 
(platelet count lower than 100 G/l).
Until recently, there was no drug to slow MF progres-
sion or to control systemic symptoms. Ruxolitinib — an 
inhibitor of JAK1/JAK2 kinase — is the first and, at 
present, only registered drug for MF that has changed 
this calamitous situation. It was approved by the Food 
and Drug Administration (FDA) in the USA in 2011 to 
treat patients with intermediate- or high-risk accord-
ing to IPSS. In 2012, the European Medicines Agency 
(EMA) registered ruxolitinib in the EU to treat pa-
tients with MF, who had splenomegaly and/or systemic 
symptoms. Both decisions were based on the results of 
two phase III trials: COMFORT-I and COMFORT-II. 
The trials proved effectiveness of ruxolitinib in reducing 
splenic volume and in decreasing constitutive symptoms 
in MF patients with and without V617F mutation. 
Combined analysis of OS after three years of follow-up 
showed over 30% reduction in death risk in patients 
receiving ruxolitinib when compared to best available 
therapy or placebo. The described results and further 
statistical analyses led to the reimbursing ruxolitinib in 
Poland on 1st January 2017. Now the drug is available 
as a part of the Polish National Health Fund Drug 
Program, which includes patients with both primary 
and secondary MF, intermediate (2) or high IPSS risk, 
splenomegaly (spleen palpable ≥ 5 cm under ribs and/or 
splenomegaly present in ultrasound examination), and 
systemic symptoms. 
Of utmost importance, ruxolitinib can be used in MF 
patients scheduled to receive allogenic haematopoietic 
stem cell transplantation (allo-HSCT). A decrease in 
concentration of proinflammatory cytokines, reduction 
of systematic symptom burden, shrinkage of spleen, and 
improvement of physical performance achieved before 
transplantation can lead to lower mortality and better 
outcomes associated with bone marrow transplant. Ac-
cording to European Leukaemia Net (ELN) and Eu-
ropean Society for Blood and Marrow Transplantation 
(EBMT) guidelines, treatment with ruxolitinib should be 
initiated at least two months before a planned transplan-
tation. The ruxolitinib dose should be gradually reduced 
5–7 days before conditioning and withdrawn one day 
prior to the procedure. Retrospective analyses suggest 
that the presence of HMR mutations significantly reduce 
duration of response to ruxolitinib. Therefore, in pa-
tients with HMR mutations, who are qualified for bone 
marrow transplant, treatment with ruxolitinib should be 
restrained to the period before transplantation, without 
postponement of this potentially curative procedure. 
However, ruxolitinib can lead to numerous adverse 
events, both haematological and non-haematological. 
Knowledge of the toxicity profile and proper adverse 
event management is required for effective and safe 
treatment. The article below presents the clinical aspects 
of ruxolitinib treatment in patients with MF, including 
groups with different clinical, laboratory, and pathologi-
cal features. Expert opinions are supported with litera-
ture data and provide valuable advice for haematologists 
in their daily practice. 
Ruxolitinib in patients with liver injury
The mean age of patients with MF is 65.9 years 
and with polycythaemia vera (PV) — 60.8 years [1]. 
This population is characterised by numerous co-
morbidities, including the presence of liver injury 
detected in physical examination, laboratory results, 
or in radiological imaging. With rising age, the rate 
of patients with hepatopathy increases, mostly due 
to toxic (alcohol, drugs) or metabolic (diabetes, 
hyperlipidaemias) factors. A significant proportion 
of hepatopathies arise from common infections with 
hepatitis B virus (HBV) or hepatitis C virus (HVC). 
Another significant factor responsible for hepatopa-
thy in patients with myeloproliferative diseases is 
extra-medullar haematopoiesis, usually in the liver. 
As a result, hepatomegaly might be present in more 
than half of all patients with MF. One of the most 
common non-haematological adverse events observed 
with ruxolitinib in registration trials was an increase 
in aminotransferases activity. This might be observed 
in about 20–30% of treated patients. Additionally, 
ruxolitinib elimination might be prolonged in patients 
with liver insufficiency [2].
Evaluation of liver function is required before 
ruxolitinib treatment initiation. Laboratory studies 
should include aminotransferase activity and bilirubin 
concentration. Patients qualified for ruxolitinib treat-
ment should have bilirubin concentration not higher 
than two-fold of the upper limit of normal (ULN) and 
alanine and aspartate aminotransferase activity lower 
than 2.5-fold of ULN. In patients with aminotransferases 
and/or bilirubin elevated below mentioned thresholds, 
detailed diagnostics should be undertaken. This is cru-
cial because ruxolitinib treatment might lead to further 
increases in aminotransferase activity due to its hepato-
toxic potential. Patients with elevated liver exams should 
be evaluated for the presence of active HBV or HCV 
hepatitis (HBsAg, anti-HBc, anti-HCV). Positive results 
should mitigate quantitative assessment for HBV-DNA 
and HCV-RNA. Infectious diseases specialist consulta-
tion might be required. Another possible cause of liver 
injury might be abuse of non-steroidal anti-inflammatory 
drugs. The most important task should be withdrawal of 
the over-used drugs. Liver regeneration may be support-
ed with phospholipids (Esseliv forte, Essentiale forte, 
Essentialne Vital) or silymarin preparations (Sylimarol 
Vita). In patients with primary bone marrow fibrosis, 
who require numerous blood transfusions, secondary 
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haemochromatosis might be considered as a source of 
liver damage. Such patients should be monitored for 
ferritin concentration.
Patients with significant liver injury, defined as an 
increase in aminotransferase ≥ 2.5-fold ULN and in-
crease in bilirubin concentration ≥ 2-fold ULN, require 
50% reduction of ruxolitinib dose. The most important 
factor influencing initial ruxolitinib dose is the number 
of platelets (PLT). For example, for a patient with ala-
nine aminotransferase increase of 1.5-fold over ULN 
and PLT number of 250 G/l, the initial treatment dose 
should be 10 mg of ruxolitinib administered twice daily. 
Monitoring with complete blood count, aminotrans-
ferase activity, and bilirubin concentration is required 
every 1–2 weeks for the first six weeks of treatment. 
If increased aminotransferase activity persist or if the 
PLT number decreases, the ruxolitinib dose should be 
again reduced.
Interactions of ruxolitinib with other drugs
Cytochrome P450 (CYP) inhibitors
Studies evaluating ruxolitinib in vivo showed that 
CYP3A4 is the main isoenzyme responsible for its me-
tabolism. Patients treated with ruxolitinib may receive 
other drugs metabolised through the same enzymatic 
pathway. If ruxolitinib is administered simultaneously 
with strong CYP3A4 inhibitors or double CYP2C9 and 
CYP3A4 inhibitors (e.g. fluconazole), ruxolitinib dose 
should be reduced by 50% in two daily doses. Intensified 
monitoring of haematological parameters and regular 
physical examination screening for liver injury is ad-
vised. Strong CYP3A4 inhibitors include: boceprevir, 
clarithromycin, indinavir, itraconazole, ketoconazole, 
lopinavir, ritonavir, mibefradil, nefazodone, nelfinavir, 
posaconazole, saquinavir, telaprevir, telithromycin, 
and voriconazole.
The ruxolitinib dose should not be reduced if the 
drug is given simultaneously with weak or moderate 
CYP3A4 inhibitors. These include ciprofloxacin, eryth-
romycin, amprenavir, atazanavir, diltiazem, and cimeti-
dine. However, patients should be closely monitored for 
potential cytopaenia when moderate CYP3A4 inhibitor 
treatment is initiated. Concomitant treatment with 
ruxolitinib and cytoreductive drugs or haematopoietic 
growth factors was not studied, and therefore the safety 
and efficiency of such treatment is unknown. Selective 
serotonin reuptake inhibitors (SSRI) increase serum 
ruxolitinib concentration because they inhibit activity of 
CYP3A4 isoenzymes. Such SSRIs include: fluoxetine, 
fluvoxamine, sertraline, and paroxetine. In patients 
receiving ruxolitinib, antidepressants with a mode of 
action different from SSRI are advised.  
CYP3A4 inductors
Patients requiring chronic treatment with CYP3A4 
inductors (such as avasimibe, carbamazepine, pheno-
barbital, phenytoin, rifabutin, rifampicin) should be 
closely monitored. Changes in CYP3A4 activity have 
limited impact on pharmacodynamics of ruxolitinib and 
is insignificant from a clinical standpoint. The dose of 
ruxolitinib can be gradually increased, considering the 
safety and effectiveness of treatment.
Infections
In retrospective analyses of patients with MF treated 
with ruxolitinib, about 20% develop infections, 90% 
of which are bacterial. Factors associated with infec-
tions are age over 65 years and concomitant treatment 
with corticosteroids.
Increased risk of infections with atypical strains of 
mycobacteria, pneumocystis, and reactivation of type B 
hepatitis should be noticed. Screening for human immu-
nodeficiency virus (HIV), HBV, and HCV before ruxoli-
tinib initiation is strongly encouraged. All patients with 
MF treated with ruxolitinib in clinical trials were offered 
annual influenza vaccination and pneumococcal vaccina-
tion because ruxolitinib treatment may result in immu-
nodeficiency due to its potential to impair functioning of 
T cells, dendritic cells, and natural killer (NK) cells. For 
the same reason, patients treated with ruxolitinib must 
not receive live vaccinations. Fungal infections should 
be closely controlled because most antifungal drugs 
are CYP2C9 and CYP3A4 isoenzyme inhibitors and 
can lower therapeutic activity of ruxolitinib. Despite 
no pharmacological interaction between ruxolitinib and 
steroids, their concomitant usage is not recommended 
due to the unfavourable impact on cell-mediated im-
munity. Opportunistic infections, such as mycobacterial 
and pneumocystis infections, were described in patients 
treated with ruxolitinib and steroids. Similarly, despite 
no interaction between ruxolitinib and thalidomide 
described, both drugs have myelosuppressive potential 
and therefore patients receiving them simultaneously 
should be carefully monitored.
Ruxolitinib treatment in patients  
with anaemia. When to reduce the dose 
and when to withdraw therapy?
Anaemia is present in 35–54% of patients with MF at 
diagnosis and is considered an unfavourable prognostic 
factor [3]. With the course of the disease, the rate of 
anaemia rises and after a year is present in 47–64% of 
patients [3–6]. Ruxolitinib’s mode of action, as well as 
the pathophysiological mechanism present in MF, result 
170
OncOlOgy in clinical practice 2019, Vol. 15, No. 3
in anaemia (with Hb concentration lower than 10 g/dl), 
being one of the most common adverse events. In both 
the COMFORT-I and COMFORT-II trials, patients re-
ceiving ruxolitinib experienced a decrease in Hb concen-
tration during the first 12 weeks, with a nadir between 
the 8th and 12th week. Additionally, in both trials after 
24 weeks of treatment, the Hb concentration increased 
to over 10 g/dl and stabilised at that level, which was 
independent of blood transfusions or ruxolitinib dose 
reductions [6–9]. Long-term observation from the COM-
FORT-I trial suggests that the incidence of new anaemia 
episodes grade 3 or 4 according to Common Termino-
logy Criteria For Adverse Events (CTCAE) decreased 
with the length of treatment [10] and is not significantly 
higher than in patients receiving placebo [11]. These 
observations are confirmed by routine clinical practice. 
Anaemia is present in 70–75% of patients treated with 
ruxolitinib, usually during the first three months of treat-
ment [12]. In most patients, the Hb concentration rises 
and stabilises thereafter. Analyses of data obtained in 
the COMFORT trials indicate that ruxolitinib-induced 
anaemia is not a negative prognostic factor and does 
not affect OS. For most experts who treat patients with 
MF, an Hb concentration decrease in the first weeks of 
ruxolitinib treatment is not an indication to reduce the 
dose or withdraw ruxolitinib, because this may lead to 
recurrence of symptoms present at the treatment ini-
tiation, usually within the first 10 days [12]. In patients 
without anaemia at the time of treatment initiation (e.g. 
with Hb concentration of 12 g/dl), who experienced 
decrease of Hb concentration to about 8.5 g/dl along 
with benefit from ruxolitinib, continuation of treatment 
with a possible dose reduction can be recommended. 
Nevertheless, most experts stress that the degree of 
anaemia is rarely the only reason for dose adjustment. 
In patients with anaemia and Hb concentration lower 
than 10 g/dl at the time of therapy initiation, the starting 
dose should be 10 mg twice daily. In patients dependent 
on blood transfusions, the recommended starting dose 
is 5 mg twice daily with a possible increase if tolerated. 
The initial three months of treatment are usually crucial 
to adjust doses for each patient [12].
A subgroup of patients do not achieve stabilisation of 
anaemia after the first three months of ruxolitinib treat-
ment. Most experts agree that ruxolitinib dose reduction 
due to anaemia or blood transfusion dependency is not 
necessary, unless the decrease in Hb is substantial (e.g. 
from 11 g/dl to 6 g/dl) [12]. A mild decrease in Hb con-
centration (e.g. from 11 g/dl to 9 g/dl) is usually accept-
able if the patient does not develop significant fatigue. 
In the case of Hb decrease from, as an example, 10 g/dl 
to less than 8 g/dl and concomitant significant fatigue, 
the decision about dose reduction should be preceded 
by consideration of whether symptoms associated with 
anaemia provide more burden than symptoms related 
to MF. The decision about dose reduction might be in-
fluenced by the patient’s age. The treatment in younger 
patients might be more intensive than in patients older 
than 70 years, who require a more cautious approach. In 
patients who have low Hb concentration despite blood 
transfusions, along with a significant fatigue, and who 
prefer dose reduction despite adequate PLT number, 
dose reduction from the initial 20 mg twice daily to 
15 mg or even 10 mg twice daily might be considered. 
The reduced dose should be continued with a close 
follow-up as long as the patient maintains response 
[12]. If an increase in Hb is observed, ruxolitinib dose 
escalation should be considered. If no change in Hb 
concentration is seen, erythropoiesis-stimulating agents 
(ESA) might be considered. In patients who develop 
rapid and significant decrease of Hb (to less than 6 g/dl) 
after prolonged treatment (e.g. 6–8 months) or who 
require blood transfusion more often than biweekly and 
who have recurrence of systemic symptoms and limited 
reduction of spleen volume, ruxolitinib withdrawal may 
be considered. The decision regarding dose reduction 
or ruxolitinib withdrawal should be taken individually, 
after discussion with the patient. Some patients might 
prefer continuation of treatment because it provides 
substantial reduction of MF symptoms, while others 
might prefer discontinuation to avoid frequent blood 
transfusions [12].
Erythropoietin in patients with myelofibrosis treated 
with ruxolitinib
Erythropoiesis-stimulating agents acts through the 
same pathway as endogenous erythropoietin, the con-
centration of which increases in patients treated with 
ruxolitinib as a result of JAK2 pathway inhibition and 
suppression of proliferation and final differentiation of 
erythropoietic precursor cells. Therefore, it might be 
expected that ESA administration would provide limited 
benefit. However, it seems that for the increase in mean 
number of circulating erythrocytes the erythropoietin 
serum concentration is less important than its mean 
serum half-life time. Most currently used ESAs are 
characterised by a prolonged half-life when compared 
to endogenous erythropoietin and therefore may offer 
clinical benefit. ESA were used in 13 from 146 patients 
(9%) treated with ruxolitinib in COMFORT-II trial. 
Darbepoetin alpha was administered to three patients 
in doses 40–300 μg, 150–300 μg, and 500 μg; epoetin 
alpha was used in nine patients in doses between 10 and 
40 thousand units; another erythropoietin preparation 
was administered to one patient at doses between 10 and 
20 thousand units. Mean doses of ruxolitinib adminis-
tered to patients receiving ESA and not receiving ESA 
were similar. Additionally, rates of patients requiring 
dose reductions were also similar. Due to the limited 
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number of this population, no statistical analyses com-
paring patients receiving and not receiving ESA were 
possible. Compared with lowest Hb concentration be-
fore ESA initiation, the lowest Hb concentration during 
first three months of ESA administration was increased 
in three patients, stable in seven patients, and lower in 
two patients. After three months of ESA treatment, Hb 
increase was observed in six patients (mean rise 7 g/dl) 
and Hb decrease in two patients (no data was reported 
regarding another five patients). In the analogic period, 
mean blood transfusion number decreased in two pa-
tients, was stable in one patient, and increased in three 
patients. Seven patients, who were independent of blood 
transfusion before ESA initiation, remained independ-
ent after three months of ESA treatment. Six weeks 
before ESA initiation grade 3 and 4 anaemia (accord-
ing to CTCAE) was noticed in 10 among all 13 patients 
(77%). After six weeks of ESA treatment, in seven out 
of 13 patients (54%) anaemia grade decreased to grade 
2 according to CTCAE. Among serious adverse events 
reported in eight patients receiving ESA, one episode 
of pulmonary embolism was judged to be ESA-related 
[3]. Results of other clinical trials indicate that ESA 
administration has limited effectiveness in MF patients 
who are blood transfusion dependent, have significant 
splenomegaly, have endogenous erythropoietin con-
centration of over 125 units/l, or have homozygotic 
mutation of JAK2 gene [9]. No patient with normal 
endogenous erythropoietin concentration responded to 
ESA in another trial [11]. In a different trial undertaken 
in Mayo Clinic, no difference in response to ESA was 
seen regardless of initial erythropoietin concentration 
and was generally considered to be low (in 23% patients) 
[11]. Doubts regarding safety and possible association 
with leukaemic transformation have led to ESA being 
unrecommended in patients with MF, who are blood 
transfusion dependent or who have Hb concentration 
higher than 10 g/dl before treatment initiation [9, 11, 13]. 
The benefit seen in some patients receiving ESA in the 
COMFORT-II trial might be due to the prolonged ESA 
half-life compared to endogenous erythropoietin, and 
to the relatively short half-life of ruxolitinib. Obtained 
results suggest that in this group of patients ESA can 
be administered safely, without any negative impact on 
ruxolitinib effectiveness, and might be used to maintain 
ruxolitinib-related anaemia in the future. 
Ruxolitinib in patients dependent on 
blood transfusions and with low PLT 
count
Anaemia and thrombocytopaenia are clinical mani-
festations of the advanced, fibrotic phase of myelofibro-
sis. The main mechanism leading to the development 
of these symptoms is suppression of erythropoietic and 
thrombopoietic precursors by progressive fibrosis in 
bone marrow and excessive degradation of erythrocytes 
and thrombocytes in an enlarged spleen. PLT count 
lower than 100 G/l, Hg concentration lower than 10 G/l, 
and blood transfusion dependency are poor prognostic 
factors and were included in IPSS, DIPSS, and DIPSS 
Plus classifications [14]. It is estimated that at the 
time of MF diagnosis anaemia with Hb concentration 
lower than 10 g/dl is present in 35–50% of patients and 
thrombocytopaenia with PLT count lower than 100 G/l 
is present in about 25% of patients [15]. Patients who 
begin treatment with ruxolitinib usually experience 
anaemia and thrombocytopaenia as a result of inhibition 
of JAK2 kinase-dependent erythropoiesis and throm-
bopoiesis. Both anaemia and thrombocytopaenia are 
strictly correlated with ruxolitinib dose. Patients with 
a tendency to develop thrombocytopaenia and anaemia 
should be carefully monitored. Avoiding significant 
decrease of platelet or erythrocyte count may limit 
the risk of serious adverse events, especially haemor-
rhages. Dose reduction is the most appropriate way of 
action in case of significant anaemia and/or thrombocy-
topaenia. Even temporary ruxolitinib withdrawal should 
be avoided because this may result in a flair-effect. Pa-
tients with severe decrease in Hb concentration and/or 
PLT count should receive packed red blood cells and/or 
platelet concentrate. 
The first data regarding frequency of anaemia and 
thrombocytopaenia in patients treated with ruxolitinib 
came from the COMFORT-I and COMFORT-II trials. 
This evidence was the basis for recommendations 
regarding ruxolitinib dose reductions and interrup-
tions. Because the first 8–12 weeks of treatment are as-
sociated with the highest risk of thrombocytopaenia, the 
initial ruxolitinib dose should be based on pre-treatment 
PLT count (PLT > 200 G/l — 2 × 20 mg, PLT 100 G/l to 
200 G/l — 2 × 15 mg, PLT 50 G/l to 100 G/l — 2 × 5 mg). 
If the PLT count decreases below 50 G/l during ruxoli-
tinib treatment, the dose should be slowly reduced and 
then, if necessary, ruxolitinib may be withdrawn [16–19]. 
Subsequent clinical trials (JUMP, EXPAND), which 
recruited patients with PLT count lower than in COM-
FORT trials, allowed the development of guidelines 
for ruxolitinib dose reductions in cases of more sever 
thrombocytopaenia. In American practice, ruxolitinib 
is withdrawn after the PLT count falls below 25 G/l, 
according to the Summary of Product Characteristics 
accepted by FDA. Because dose reduction might have 
a negative impact on treatment effectiveness, the highest 
tolerable dose should be reintroduced once the grade 
of toxicity allows [16]. 
The COMFORT trials showed that 61% of patients 
receiving ruxolitinib, who had normal pre-treatment 
haemoglobin concentration, developed anaemia, and 
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69% of patients with pre-treatment experienced anae-
mia worsening. Red blood cell parameters achieve their 
lowest point usually between eight and 12 weeks after 
treatment initiation and return to baseline after 24 weeks 
of therapy. In the case of anaemia, even with very low 
Hb concentration, ruxolitinib withdrawal is not recom-
mended because the anaemia can be managed with blood 
transfusions and dose reductions, although this was not 
recommended in COMFORT trials. Exploratory analysis 
of the COMFORT trial data showed that, despite the fact 
that any degree of pre-treatment anaemia is a negative 
prognostic factor, anaemia associated with ruxolitinib 
treatment does not affect the patient’s prognosis [15]. 
Maintenance of optimal ruxolitinib dose, adjusted 
to PLT count and Hb concentration, requires regular 
evaluation of complete blood count (CBC), especially 
during expected PLT and Hb nadir (between eight and 
12 weeks after therapy initiation). Bi-weekly laboratory 
assessment can be recommended in all patients, even 
often in patients with low PLT count, who are depend-
ent on blood transfusions. Adequate, regular laboratory 
evaluation and skilful dose maintenance might be crucial 
for successful ruxolitinib treatment [15].
IPSS and DIPSS — practice versus Drug 
Program. Which scale to use and how 
often to evaluate?
In 2009 the IWG-MRT group analysed a cohort of 
1054 patients with newly developed MF and developed 
the IPSS scale. The analysis discriminated five inde-
pendent progression risk factors: age over 65 years, 
presence of systemic symptoms, Hb concentration 
lower than 10 g/dl, hyperleukocytosis over 25 G/l, and 
the presence of at least 1% of blasts in a leukogram. 
Every factor was attributed one point. The number of 
points classifies patients to a group with low (0 points), 
intermediate-1 (1 point), intermediate-2 (2 points), or 
high risk (≥ 3 points), with median OS of, respectively, 
135, 95, 48, and 27 months [20]. 
Expansion of IPSS, which was developed for patients 
before treatment initiation, led to the DIPSS scale, 
which incorporated acquisition of risk factors during 
the course of disease and can be used at any time. The 
DIPSS scale included the same parameters as the IPSS 
scale, with a 2-point value attributed to anaemia. The 
number of points classifies patients to groups with 
low (0 points), intermediate-1 (1–2 points), interme-
diate-2 (3–4 points), and high (5–6 points) risk, with 
median OS of, respectively: not reached, 168, 48, and 
18 months [21]. The DIPSS scale can also assess risk of 
transformation to acute myeloid leukaemia: it can be 
estimated at, respectively, 0.3, 0.7, 2.6, and 8.6 cases per 
100 patient-years [22]. 
In the newer DIPSS Plus scale an additional three 
independent prognostic factors were included: blood 
transfusions dependency, unfavourable karyotype (tri-
somy 8; monosomy 7/7q–; i(17q); inv(3); monosomy 
5/5q– or 12p–; rearrangement of 11q23), and thrombo-
cytopaenia (PLT count lower than 100 G/l) [23].
The Polish National Health Fund Drug Program re-
quires attribution of potential patients to intermediate-2 or 
high-risk groups in the IPSS scale (which is based on the 
results of registration trials). If the patient was previously 
surveilled and attributed to the low-risk group, reassess-
ment with the IPSS scale is discordant with its basic as-
sumption of evaluation at the time of diagnosis. Patient 
surveillance should be undertaken with dynamic scales, 
such as DIPSS and DIPSS Plus. Unfortunately, during 
administrative controls the Drug Program is interpreted 
literally (not on the basis of merit), and therefore assess-
ment with a scale other than IPSS during patient qualifi-
cation can result in a financial fine for a controlled site. 
Prognostic scales should be actualised during each visit 
because any sign of progression might require treatment 
initiation or change. The Drug Program does not require 
further surveillance with the IPSS scale during treatment.
On a side note, it is worth mentioning that patients 
with MF, who are potential candidates for allo-HSCT, 
should not only be assessed with the aforementioned 
prognostic scales, but also undergo karyotype and mole-
cular risk factor evaluation (including CALR, JAK2, MPL, 
and ASXL1). Patients with unfavourable karyotype and/or 
so-called “triple-negative” patients (without mutation 
in either JAK2, CALR, or MPL) with ASXL1 mutation 
should be considered as candidates for allo-HSCT even 
with intermediate-1 risk prognosis in the DIPSS scale.
What, if any, antimicrobial prophylaxis 
should be administered during 
ruxolitinib treatment?
Treatment with ruxolitinib may result in immuno-
suppression, increasing the risk of infectious complica-
tions. The pathophysiological nature of this effect is 
complicated because ruxolitinib results in lower leuko-
cyte count, including granulocytes, with concomitant 
impairment of lymphocyte T, dendritic cell, and NK 
cell functioning [24]. 
Grade 3 and 4 neutropaenia (according to CTCAE) 
was noted in 7.1% of patients treated with ruxoli-
tinib and in 2% of patients treated with placebo in the 
COMFORT-I trial [10]. In the COMFORT-II trial, after 
five-year follow-up, grade 3 and 4 neutropaenia and 
leucopaenia was noted in 8.9% and 6.3% of patients, 
respectively (Tab. 1) [25].
Lussana et al. [26] review five phase III randomised 
clinical trials, six phase IV trials, and 28 case reports and 
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Table 1. Neutropaenia in patients included in the COMFORT trials (source [25])
COMFORT-I COMFORT-II
Ruxolitinib 
(n = 155)
Placebo 
(n = 151)
Ruxolitinib 
(n = 146)
BAT 
(n = 73)
Neutropaenia 19 4 NR NR
Neutropaenia ≥ grade 3 7 2 NR NR
BAT — best available therapy; NR — not reported
Table 2. Guidelines for antiviral prophylaxis during ruxolitinib therapy
Pathogen Laboratory evaluation recommended  
before treatment initiation
Prophylaxis Comments
CMV IgG+, IgM– Prophylaxis not recommended CMV-PCR might  
be considered
EBV IgG+, IgM– Prophylaxis not recommended EBV-PCR might  
be considered
VZV IgG+, IgM– Prophylaxis: acyclovir 
2 × 400 mg/d.
HSV IgG+, IgM– Prophylaxis: acyclovir 
2 × 400 mg/d.
HBV HBsAg+ Prophylaxis: lamivudine 100 mg/d.
HCV HCV–, IgG+ No prophylaxis available
CMV — cytomegalovirus; PCR — polymerase chain reaction; EBV — Epstein-Barr virus; VZV — varicella-zoster virus; HSV — herpes simplex virus; HBV — hepa-
titis B virus; HCV — hepatitis C virus
showed a statistically significant increase in the risk of 
shingles in patients treated with ruxolitinib. Data from 
the COMFORT-I and COMFORT-II trials showed that 
urinal tract infections grade 3 and 4 developed in 1% 
of patients, shingles in 4% of patients, tuberculosis in 
1% of patients, and sepsis in 3% of patients. Combined 
analysis of clinical trials demonstrated that the most 
common infections were: shingles (8%), bronchitis 
(6%), and urinary tract infections (6%). The most com-
mon case reports described tuberculosis (n = 10), HBV 
reactivation (n = 5), and Pneumocystis jirovecii infections 
(n = 2). Less common cases of bilateral retinitis caused 
by Toxoplasma gondii and confirmed viral leukoencepha-
lopathy were also reported [26].
Available data suggest that the increased infection 
risk during ruxolitinib treatment can have a clinically 
significant impact, but no recommended prophylaxis 
guidelines exist. A limited number of authors formulated 
practical tips that can be incorporated into clinical prac-
tice. Heine et al. [27] proposed undertaking laboratory 
evaluation aimed at detection of infectious agents before 
and during ruxolitinib treatment (Tab. 2). 
Antibacterial prophylaxis is generally not recom-
mended. Patients with tendencies towards urinary tract 
infections or bronchopneumonia with granulocyte count 
lower than 1 G/l may benefit from ciprofloxacin 500 mg 
administered twice daily until resolution of granulopae-
nia. Patients with positive results of Quantiferon test 
for Mycobacterium tuberculosis are advised to receive 
isoniazid 300mg daily. No prophylaxis for Pneumocystis 
jirovecii is recommended.
Because ruxolitinib treatment is not associated with 
an increased risk of fungal infection, no antifungal 
prophylaxis is recommended. It should be noted that 
many antifungal drugs are CYP enzyme inhibitors, 
and their administration might require ruxolitinib dose 
adjustment. 
If ruxolitinib is used concomitantly with strong CYP-
3A4 inhibitors or double CYP2C9 and CYP3A4 inhibi-
tors, such as fluconazole, the ruxolitinib dose should be 
reduced by 50%. A fluconazole dose of 200 mg per day 
should not be exceeded. If simultaneous administration 
of ruxolitinib and CYP enzymes inhibitors is required, 
complete blood count should be evaluated more often 
— even 1–2 times per week. 
Strong CYP3A4 inhibitors, such as clarithromycin, 
itraconazole, ketoconazole, posaconazole, and vori-
conazole, also require a 50% reduction of the ruxo-
litinib dose. Mild and moderate CYP3A4 inhibitors, 
such as ciprofloxacin and erythromycin, do not require 
ruxolitinib dose modification, but close monitoring for 
cytopaenia should be undertaken. 
Viral infections, significantly more common in 
patients receiving ruxolitinib, are a separate issue. 
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In some cases, antiviral prophylaxis with acyclovir might 
be considered (Tab. 2) [27].
Can the molecular profile of patient 
with myelofibrosis affect ruxolitinib 
effectiveness? 
In both COMFORT trials, similar ruxolitinib effec-
tiveness in reduction of splenic volume and control of 
systemic symptoms was seen in patients with and without 
V617F mutation [7, 28]. Additional analysis confirmed 
effectiveness of ruxolitinib in patients with CALR muta-
tion [29]. Similar activity of ruxolitinib in both patient 
groups confirms that the main pathogenetic mechanism 
behind MF is overactivation of JAK–STAT pathway, 
which can independent of a specific single mutation.
Patients with MF often, despite the presence of 
driver-type mutation, have additional mutations in genes 
responsible for epigenetic modulation. This includes 
genes responsible for posttranslational modification 
of histones (ASXL1, frequency 10–35%; EZH2, fre-
quency 7–10%), DNA methylation (TET2, DNMT3A, 
IDH1/2), mRNA splicing (SRFS2, SRF3B1), and DNA 
repair (TP53). The presence of at least one mutation in 
ASXL1, EZH2, SRSF2, or IDH1/2, called high-molecular 
risk (HMR,) is associated with shorter OS and higher 
risk of blastic transformation [30]. Guglielmelli et al. 
[31] analysed the impact of mutations on ruxolitinib 
effectiveness in 166 patients from the COMFORT-II 
trial. No impact of mutations was seen on treatment 
effectiveness (defined as reduction of splenomegaly 
and/or systemic symptoms) and on haematological 
toxicity profile (including anaemia and thrombocy-
topaenia). The beneficial effect of ruxolitinib on OS 
was independent of mutations associated with poor 
prognosis. After a median observation of 151 weeks, 
the predicted survival of patients treated with ruxolitinib 
in week 144 was 0.79 in the HMR group and 0.85 in 
the low-molecular risk (LMR) group, compared with, 
respectively, 0.58 and 0.71 in patients receiving the best 
available therapy (BAT). Patel et al. [32] assessed the 
impact of mutations on spleen volume reduction and on 
time to treatment discontinuation (TTD) in 95 patients 
treated with ruxolitinib in phase I/II trials. The authors 
of the analysis found a significant, negative impact of 
the presence of at least one HMR mutation on splenic 
response. Additionally, patients in the HMR group 
were characterised by a shorter TTD and OS. Spiegel 
et al. [33] evaluated correlation between mutations and 
similar parameters in a cohort of 100 patients with MF 
treated with ruxolitinib (77 patients) or momelotinib 
(23 patients). Unlike the observation of Patel et al. 
[32], this analysis showed no correlation between the 
presence of mutations and splenic response. However, 
it confirmed the negative impact of mutations on time 
to treatment failure (TTF) and OS. 
The results of the presented analysis indicate that the 
presence of mutation from the HMR group significantly 
impairs duration of response to ruxolitinib. Therefore, 
in patients with mutation, who are potential candidates 
for allo-HSCT, treatment with ruxolitinib should not 
postpone the decision regarding transplantation, and 
should be considered only as a part of preparation to 
the procedure. 
Ruxolitinib and risk of venous and 
arterial embolisms
Chronic myeloproliferative neoplasms (MPN) are 
characterised by an increased risk of venous and arte-
rial embolisms. This affects 10–30% of patients before 
and 10–20% after MPN diagnosis [34]. Thromboem-
bolic disease is most common in patients with PV and 
less common in patients with essential thrombocyto-
paenia (ET) and MF [35]. Risk factors associated with 
an increased risk of venous and arterial embolisms 
are: prior history of thromboembolic disease, pres-
ence of JAK2 V617F mutation, and leukocytosis over 
15 G/l [36]. Pathogenesis of MPN-related embolisms 
is mostly based on disfunction of red blood cells, white 
blood cells, platelets, and epithelial cells that raises 
adhesion of blood cells to endothelium [36, 37]. In 
vivo studies of JAK2+ neutrocytes showed increased 
creation of neutrophil extracellular traps (NET), 
which play a crucial role in disposal of pathogens, 
immunological reactions, and clot development [38]. 
Patients with PV have additional risk factors due to 
the presence of rheologic disturbances associated with 
increased haematocrit. 
Association between ruxolitinib and thromboem-
bolic diseases in patients with MF and PV was found 
in a metanalysis that included data from 750 patients 
participating in the COMFORT-I, COMFORT-II (pa-
tients with MF), and RESPONSE (patients with PV) 
trials [39]. The authors concluded that treatment with 
ruxolitinib was associated with lower risk of arterial and 
venous embolic disease when compared to treatment 
with placebo or BAT.
Research from Italy assessed the effectiveness and 
safety of ruxolitinib in patients with MPN (12 patients 
with MF, five with PV, and four with ET), who had his-
tory of portal vein thrombosis. No aggravation of portal 
vein thrombosis or worsening of oesophageal varices was 
seen during ruxolitinib treatment. One haemorrhagic 
adverse event was reported [40].
Effectiveness and safety of ruxolitinib treatment in 
patients with PV refractory or intolerant to hydroxycarba-
mide was assessed in the RESPONSE (222 patients) [41] 
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and RESPONSE-2 (149 patients) [42] trials. Ruxo-
litinib was more effective than BAT, with a significantly 
lower rate of thromboembolic disease in patients receiv-
ing ruxolitinib.
One phase II trial compared the effectiveness and 
safety of ruxolitinib with BAT in patients with ET 
refractory or intolerant to hydroxycarbamide [43]. No 
difference between ruxolitinib and BAT was seen in 
response rate. After two years of treatment, no diffe-
rence in rates of thromboembolic and haemorrhagic 
events was observed. Another trial evaluated the ef-
fectiveness of ruxolitinib as a second-line treatment in 
39 patients with ET [44]. Thromboembolic disease was 
seen in two patients and non-significant bleeding events 
in four patients. 
Concluding, available data suggest that treatment 
with ruxolitinib results a in lower rate of embolic disease 
in patients with MF and PV, without a similar effect seen 
in patients with ET. No increase in haemorrhagic events 
is seen in MPN patients receiving ruxolitinib.
How to withdraw ruxolitinib?  
Principles of ending therapy
According to the Polish National Health Fund Drug 
Program, ruxolitinib treatment should be stopped if 
there is no spleen size reduction is seen after three 
months of treatment and/or if the spleen size reduction 
is less than 50% as assessed in USG after six months of 
treatment. Other mentioned situations are the develop-
ment of new or a clear increase in previously present sys-
temic symptoms, as well as unacceptable toxicity despite 
proper dose reduction and/or introduction according 
to the Summary of Product Characteristics. The last 
indications for ruxolitinib withdrawal are loss of gained 
response (assessed every six months) and transformation 
into acute leukaemia.
The most common adverse events seen with ruxoli-
tinib — dose-dependent anaemia and thrombocytopae-
nia — developed in, respectively, 40.4% and 44.5% of 
patients in the COMFORT-II trial and rarely caused 
ruxolitinib withdrawal [45]. Other common toxicities 
include: leukopaenia, diarrhoea, bleeding, infections, 
thromboembolic events, arterial hypertension, and 
elevated liver enzymes. The decision about stopping 
ruxolitinib should include the notion that adverse events 
are most common in the first six months of treatment 
and usually decrease thereafter [46]. 
Long-term observations indicate that ruxolitinib 
needs to be stopped in 55% of patients after three-year 
follow-up (data from COMFORT-I and -II trials) [46]. 
Median OS after stopping ruxolitinib is 14 months [47].
Severe adverse reactions after ruxolitinib with-
drawal, called ruxolitinib distress syndrome (RDS), 
are described in the literature. As confirmed in clinical 
trials, benefit from ruxolitinib was associated with a sig-
nificant decrease in serum pro-inflammatory cytokines, 
such as IL-6, IL-1RA, TNFa, macrophage inhibitory 
protein 1b (MIP-1b), or C-reactive protein (CRP) [48]. 
Therefore, RDS might be caused by a rapid increase 
in previously low cytokine concentration. Ruxolitinib 
distress syndrome includes various clinical manifes-
tations, from brisk reoccurrence of disease-related 
symptoms (including fast increase of spleen size and 
development of cytopaenia) to more severe conditions 
such as acute respiratory distress syndrome (ARDS), 
disseminated intravascular coagulation (DIC), spleen 
infarction, tumour lysis-like syndrome, or tumour septic 
shock-like syndrome.
Luckily, RDS is very rare, and only 10 cases have 
been described in the literature so far. Tefferi et al. [49] 
described RDS in five out of 47 patients who finished 
ruxolitinib treatment. Among them, three developed 
ARDS, from who two required mechanical ventilation 
and catecholamine infusion due to septic shock-like syn-
drome; one other patient developed DIC-like syndrome. 
In the COMFORT-I trial one patient experienced fever, 
acute respiratory failure, and splenic haemorrhage with 
infarction [7]. Other literature reports describe tumour 
lysis-like syndrome [50], ARDS [51], and recurring res-
piratory failure that resolved each time ruxolitinib was 
re-initiated [52]. RDS can be diagnosed only after exclu-
sion of other possible causes and no clinical, laboratory 
or pathology finding can be called pathognomonic. Time 
to RDS occurrence varies from less than 24 hours to 
more than three weeks after ruxolitinib withdrawal [48].
According to the available literature, management 
of RDS should include not only supportive care, anti-
biotics, and mechanical ventilation if necessary, but also 
steroids or re-introduction of ruxolitinib, which can be 
switched to other JAK2 inhibitors after achieving RDS 
remission. Because RDS is very rare, no data enable 
formulation of ruxolitinib withdrawal guidelines. The 
authors of RDS case reports suggest close observation, 
slow dose decrease, and concomitant introduction of 
steroids [48, 49].
Management of ruxolitinib-associated 
hyperleukocytosis
Leukocytosis can be found in CBC of about 10–25% 
of patients with MF [53]. An increase in leukocyte count 
to over 25 G/l is a poor prognostic factor included in the 
IPSS, DIPSS, and DIPSS Plus scales [20, 21, 23]. In most 
patients, ruxolitinib has little to no effect on leukocyte 
count. In the COMFORT-I trial, mean pre-treatment 
leukocytosis was between 20 and 30 G/l and decreased 
to 15–20 G/l during treatment [54]. Only few cases of 
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grade 3 and 4 leukopaenia, according to World Health 
Organisation classification, developed. Some patients 
may experience an increase in leukocytosis or even 
hyperleukocytosis (leukocyte count of > 50–100 G/l). 
Every such case should be evaluated for the rate of 
peripheral myeloblasts, to exclude MF transformation 
into leukaemia. 
A drug that might be used to decrease the leukocyte 
count is hydroxyurea (HU) — a cytostatic drug com-
monly used in patients with MF [55]. Until today, there 
are only a limited number of reports describing concomi-
tant usage of ruxolitinib and HU in patients with MF [56, 
57]. Caocci et al. [56] reported a case of a female patient 
in whom ruxolitinib treatment resulted in a leukocyte 
count increase up to 94 G/l and subsequent reoccurrence 
of systemic symptoms. After initiation of HU at a daily 
dose of 500 mg, the leukocyte count returned to normal 
and systemic symptoms vanished. In another patient 
with hyperleukocytosis, combined ruxolitinib and HU 
treatment resulted in normalisation of leukocyte count, 
a decrease in spleen size, improvement in systemic 
symptoms, and lower blood transfusion dependency 
[57]. It seems that for patients who receive ruxolitinib 
and develop a significant rise in leukocyte count, HU 
might be a safe and efficient therapeutic option.
Metabolic disorders in patients 
receiving ruxolitinib
Metabolic disorders, such as decrease in body weight, 
low serum cholesterol and albumin concentration, or 
cachexia, are a common problem in patients with MF, 
especially in more advanced cases [58–60]. If present, 
they significantly impair the patient’s prognosis [20, 23, 
58–60]. The aetiology of metabolic disorders is multi-
factorial [4, 22, 23, 61–66]. On the one hand, massive 
splenomegaly can lead to abdominal symptoms (pain, 
nausea, vomiting, early satiety) and decrease appetite 
[4, 66]. On the other hand, aberration in JAK–STAT 
pathway signalling can lead to overproduction of 
pro-inflammatory cytokines such as IL-6 or TNFa, which 
induce chronic inflammation, hypercatabolic state, loss 
of body weight, induction of cachexia, and reduction of 
liver albumin production [62–64].
According to the results of two clinical trials, the 
COMFORT-I study (ruxolitinib vs. placebo) and the 
COMFORT-II study (ruxolitinib vs. BAT), ruxolitinib 
can efficiently inhibit JAK1 and JAK2 kinases, leading 
to spleen volume reduction (probably due to reduc-
tion of extra-medullar haematopoiesis), a decrease in 
systemic symptoms and improvement of quality-of-life 
in patients with MF. Reduction of pro-inflammatory 
cytokine concentration, TNFa, IL-6, and CRP might 
also play role [4, 65].
A gradual increase in body weight of patients receiv-
ing ruxolitinib has been noticed in the COMFORT-I, 
COMFORT-II, and COMFORT-III trials [7, 64, 66]. 
This observation was confirmed in post hoc analysis of 
long-term (96 weeks) data from the COMFORT-I trial 
[61]. Among patients receiving ruxolitinib, 96.1% of 
patients achieved any body weight increase (mean 
3.9 kg, as opposed to mean loss of 1.9 kg in patients 
receiving placebo; p < 0,0001) after 24 weeks of therapy, 
with comparable results after 36 weeks and even more 
profound gain of a mean 5.7 kg after 96 weeks. Body 
mass index (BMI) analysis showed a significant mean 
gain of 1.4 kg/m2 after 24 weeks in the ruxolitinib arm 
(compared with a mean 0.7 kg/m2 loss in the placebo 
arm; p < 0.0001), with comparable results after 36 weeks 
of treatment. 
Additionally, the COMFORT-I trial also evaluated 
the concentration of leptin as a marker of adipose tissue. 
In patients receiving ruxolitinib, a more than two-fold 
increase in mean plasma leptin concentration was noted 
after four weeks of treatment and remained significant 
after 24 weeks. In patients receiving placebo a slight 
decrease in leptin concentration was noted during the 
same observation period [65].
In a post hoc analysis of the COMFORT-I trial, 
a rise in cholesterol concentration was noted in 96.8% 
of patients receiving ruxolitinib. After 24 weeks cho-
lesterol increased 26.4% from baseline (29.5 mg/dl) in 
patients receiving ruxolitinib compared to a 3.3% fall 
(4.98 mg/dl) in patients receiving placebo. The choles-
terol increase in the ruxolitinib group was maintained 
after 96 weeks of therapy (35.8% increase from baseline, 
38 mg/dl). It should be emphasised that cholesterol 
concentration did not exceed 240 mg/dl of complete 
cholesterol and 160 mg/dl of low-density lipoprotein 
(LDL) cholesterol, thus not resulting in a higher risk 
of hypercholesterolaemia [61]. 
As with cholesterol, post hoc analysis of COM-
FORT-I data showed that 94.8% of patients receiving 
ruxolitinib experienced a rise in albumin concentra-
tion. The increase reached 5.8% (2.3 g/dl) at week 
24 (compared to 1.7% [0.8 g/dl] decrease with placebo; 
p < 0.0001), with a stable results at week 10 and an ad-
ditional rise of 7.6% (3.1 g/dl) at week 96 [61]. 
Both body mass increase and rise of cholesterol and 
albumin concentration was independent of the degree 
of spleen size reduction (≥ 35% vs. 10–35% vs. < 10%) 
and of the degree of systemic symptom reduction as-
sessed with MyeloProliferative Neoplasm — Total 
Symptom Score (MPN-TSS) (not less than 50% vs. less 
than 50%) [61].
To sum up, ruxolitinib treatment, through inhibi-
tion of JAK1 and JAK2 kinases, leads to a decrease of 
pro-inflammatory cytokines concentration (IL-6 and 
TNFa). This results in reduction of chronic inflamma-
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tion and systemic symptoms, suppression of hyperca-
tabolism, and decrease in spleen size. Secondary to this, 
but no less important, is the observation that patients 
receiving ruxolitinib experience gradual and consist-
ent (for over 96 weeks) improvement in body weight, 
cholesterol concentration (without increased risk of 
hypercholesterolaemia and cardio-vascular disorders), 
and albumin concentration. This effect might be par-
tially responsible for the survival benefit associated with 
ruxolitinib in this patient population. Close follow-up 
of nutritional markers might provide valuable insights 
during ruxolitinib therapy.
Conclusions
The presented contemplations regarding clinical as-
pects of ruxolitinib treatment in patients with MF should 
provide answers to basic questions and doubts that may 
arise during therapy. The discussed issues concentrate 
mostly on management of patients with distinctive 
clinical and/or pathological profile and on dealing with 
certain adverse events. Crucial value can be attributed 
to proper monitoring of systemic symptoms, which are 
the best indicators of MF activity and can also overlap 
with possible adverse events.
The most important symptoms of MF are spleno-
megaly and cytokine-induced systemic symptoms that 
include weight loss, night sweats, fatigue, fever, and 
pruritus. Because the presence of systemic symptoms 
is required to qualify patients to the Polish National 
Health Fund Drug Program, and subsequent changes 
in symptoms provide insight into treatment effective-
ness, objective symptom evaluation is crucial. This can 
be achieved with the MPN-TSS scale, which includes: 
fatigue; early satiety; discomfort in abdomen; decrease 
in activity and concentration; night sweats; pruritus; 
bone pains; fever; and unintentional weight loss.
Other important issue includes ruxolitinib distress 
syndrome, which can arise when ruxolitinib is withdrawn 
rapidly. Because this may lead to fierce and sympto-
matic cytokine storm, ruxolitinib withdrawal should be 
a gradual process. Nonetheless, stopping ruxolitinib may 
result in reoccurrence of systemic symptoms and an in-
crease in spleen size. The decision regarding ruxolitinib 
withdrawal should be taken after careful deliberation 
and should be properly planned to limit the possibility 
of unexpected complications. 
Patients with MF receiving ruxolitinib should be 
closely monitored to detect both haematological and 
non-haematological adverse events. The most common 
haematological adverse events are anaemia and throm-
bocytopaenia. In the COMFORT-I and COMFORT-II 
trials, all-grade anaemia according to CTCAE occurred 
in nearly all treated patients, with grade 3 and 4 events 
in 45.2% of patients in the COMFORT-I and 62% of 
patients in the COMFORT-II trial. Anaemia usually 
develops within the first eight weeks of treatment, with 
the nadir of Hb concentration between weeks 8 and 
12, and then gradually increases and stabilises after six 
months of therapy. More than 50% of patients require 
blood transfusions, but ruxolitinib-related anaemia 
rarely requires dose modification or interruption. Other 
causes of anaemia should be ruled out, just as progres-
sion of MF itself. 
All grade thrombocytopaenia, according to 
CTCAE, occurred in 70% of patients in the COM-
FORT-I and COMFORT-II trials. About 11% of pa-
tients experienced grade 3 and 4 thrombocytopaenia. 
Median time to thrombocytopaenia development was 
about eight weeks. Thrombocytopaenia was reversible 
after dose reduction or drug interruption, with a me-
dian time to PLT count recovery to over 50 G/l of two 
weeks. Decrease in PLT count might require ruxoli-
tinib dose adjustment, mostly to avoid any treatment 
interruption that may limit therapy effectiveness. Pa-
tients with PLT count lower than 50 G/l should not be 
qualified for treatment with ruxolitinib. An additional 
indication for treatment interruption is neutropaenia 
greater than 0.5 G/l.
Regardless of PLT count, ruxolitinib treatment often 
results in haemorrhagic adverse events, most commonly 
subcutaneous haemorrhages, occurring in about 20% of 
patients. In the COMFORT-I and COMFORT-II trials, 
gastrointestinal bleeding of all grades occurred in 5% of 
patients and grade 3 and 4 events in 1.3% of patients. In-
tracranial bleeding developed in 1% of patients. Other 
bleeding events (including nosebleed, haematuria, or 
procedural bleedings) of all grade occurred in 13% of 
patients and of grade 3 and 4 in 2.3% of patients.
Non-haematological adverse events associated with 
ruxolitinib include headaches, dizziness (in about 15% 
of patients), diarrhoea, and mild to moderate increase in 
AlAt and AspAT activity (in about 20% of patients). Ad-
ditionally, as a result of reduction of pro-inflammatory 
cytokine concentration, ruxolitinib exhibits immunosup-
pressive properties, including inhibition of dendritic cell 
activity, which leads to the suppression of CD4+ and 
CD8+ lymphocytes. Consequently, patients treated 
with ruxolitinib are more prone to infections, including 
opportunistic ones. Data from the COMFORT trials 
show increased risk of urinary tract infections and Her-
pes zoster infections in patients treated with ruxolitinib. 
Cases of HBV reactivation, tuberculosis, Cryptococcus 
neoformans pneumonia, toxoplasmosis uveitis, and 
progressive multifocal leukoencephalopathy were also 
reported. Therefore, screening for tuberculosis and 
hepatotropic viruses as part of routine pre-treatment 
evaluation should be considered. If positive, proper 
prophylaxis should be undertaken. 
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Ruxolitinib is excreted through kidneys and, to 
a lesser degree, through the digestive tract. Patients 
with severe renal impairment should receive reduced 
initial dose and patients with end-stage renal failure 
undergoing dialysis should receive a single daily dose 
after each dialysis. Patients with impaired liver function 
should receive 50% of the standard dose. 
Because ruxolitinib interacts with numerous other 
agents, simultaneously used drugs should be revised 
and the ruxolitinib dose reduced if necessary. This is 
mostly due to the ruxolitinib metabolism, which involves 
mainly cytochrome CYP3A4 and partially CYP2C9. Flu-
conazole, a strong inhibitor of both mentioned cy-
tochromes, increases ruxolitinib serum concentration 
by 100–300%. Therefore, the ruxolitinib dose should 
be reduced by 50%, with the same dosing schedule, if 
strong CYP3A4 inhibitors are administered (antifungal 
agents such as fluconazole, ketoconazole, itraconazole, 
posaconazole, voriconazole; antiviral agents such as 
boceprevir, ritonavir, nelfinavir; and antibacterial agents 
such as clarithromycin).
Patients receiving ruxolitinib simultaneously with 
CYP3A4 inducers (such as carbamazepine, phenobar-
bital, phenytoin, rifampicin, St. John’s wort) should 
be carefully monitored and ruxolitinib dose increased 
according to achieved effectiveness and safety. No 
ruxolitinib dose adjustment is required when combined 
with mild and moderate CYP3A4 inducers (such as 
ciprofloxacin, erythromycin, diltiazem, cimetidine, 
atazanavir, and amprenavir). 
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